Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Medtronic
Covington
Dow
Federal Trade Commission
Chinese Patent Office
Harvard Business School
Fish and Richardson
Boehringer Ingelheim

Generated: April 24, 2018

DrugPatentWatch Database Preview

XIMINO Drug Profile

« Back to Dashboard

Which patents cover Ximino, and what generic alternatives are available?

Ximino is a drug marketed by Sun Pharm Inds Ltd and is included in one NDA. There are seven patents protecting this drug.

This drug has thirteen patent family members in ten countries.

The generic ingredient in XIMINO is minocycline hydrochloride. There are thirteen drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
Summary for XIMINO
International Patents:13
US Patents:7
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 60
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:XIMINO at DailyMed
Drug patent expirations by year for XIMINO
Pharmacology for XIMINO
Ingredient-typeTetracyclines
Drug ClassTetracycline-class Drug
Medical Subject Heading (MeSH) Categories for XIMINO

US Patents and Regulatory Information for XIMINO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for XIMINO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 ➤ Sign Up ➤ Sign Up
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 ➤ Sign Up ➤ Sign Up
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-003 Jul 11, 2012 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for XIMINO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,722,650 Extended-release minocycline dosage forms ➤ Sign Up
9,192,615 Method for the treatment of acne and certain dosage forms thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
US Department of Justice
Merck
Julphar
Farmers Insurance
Citi
McKesson
QuintilesIMS
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.